ClinicalTrials.gg
TerminatedNCT04896632Updated Sep 28, 2023

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

A Phase 1 interventional study of INE 963 and Placebo in Healthy Volunteers, sponsored by Novartis Pharmaceuticals. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor's decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single ascending doses and multiple doses of INE963 given orally in healthy participants.

Read the detailed description

This is a randomized, participant- and investigator-blinded, placebo-controlled, single ascending and multiple oral dose study in healthy participants. The study consisted of two parts:

  • Part A was a single ascending dose (SAD) study with 6 planned cohorts: (A1, A2, A4, A5, A6 and A7) of 8 participants each and 1 cohort (A3) with 10 participants, as randomization ratio 4:1 was originally planned due to the food effect cohort. There was also an optional cohort of 8 subjects (A8).
  • Part B was a multiple dose (MAD) study with 2 planned cohort of 9 participants (B1 and B2; randomization ratio 2:1). There was also an optional cohort of 9 subjects (B3).

Cohort B2 and Optional Cohorts A8 and B3 were not dosed since the study was terminated early as per joint decision between the Principal Investigator and the Sponsor. Importantly, the decision to terminate the study early was not taken as a consequence of any safety concerns seen with INE963 administration in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Healthy male and female participants 18 to 55 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, , and laboratory tests at screening.
  3. At screening and baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the supine position Supine vital signs should be within the following ranges:

    • oral body temperature between 35.0 - 37.5 °C
    • systolic blood pressure, 90 - 140 mm Hg
    • diastolic blood pressure, 50 - 90 mm Hg
    • pulse rate, 40 - 90 bpm If vital signs are outside these ranges, the investigator may obtain up to 2 additional readings so that a total of up to 3 consecutive assessments are made. At least the last reading must be within the ranges provided above in order for the participant to qualify.
  4. Participants must weigh at least 50 kg at screening and baseline to participate in the study, and must have a (BMI) within the range of 18.0 - 32.0 kg/m2. BMI = Body weight (kg) / [Height (m)]2
  5. Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion criteria

  1. History of to any of the study treatments or or to drugs of similar chemical classes
  2. Significant illness which has not resolved within two (2) weeks prior to initial dosing.
  3. Recent (within the last three years of screening) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).
  4. Recent (within the last three years of screening) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and , treated or not treated).
  5. Known history or current arrhythmias.
  6. Known family history or known presence of long syndrome.
  7. A history of clinically significant abnormalities, or any of the following ECG abnormalities at screening and/or baseline:

    • PR > 220 msec
    • QRS complex > 120 msec
    • RR >1.5 seconds
    • QTcF > 450 msec (males)
    • QTcF > 460 msec (females)
  8. History of immunodeficiency diseases, including a positive test result.
  9. Chronic infection with (HBV) or (HCV). A positive HBV surface antigen (HBsAg) test, excludes a participant. Participants with a positive HCV antibody test should have HCV RNA levels measured. Participants with positive (detectable) HCV RNA should be excluded.
  10. History of of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years of screening, regardless of whether there is evidence of local recurrence or .
  11. Donation or loss of 450 mL or more of blood within eight weeks prior to initial dosing, or longer if required by local regulation.
  12. Plasma donation (> 450 mL) within 8 weeks prior to first dosing.
  13. Any clinically significant hematology parameters outside normal ranges at screening and/or baseline. Participants with neutrophils \<1.5 x 109/L should be excluded.
  14. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in case of participation in the study. The Investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence of any of the following at screening or baseline:

    • Inflammatory bowel disease, peptic ulcers, gastrointestinal including rectal bleeding;
    • Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
    • Pancreatic injury or pancreatitis;
    • Liver disease or liver injury as indicated by abnormal liver function tests (as defined below). (SGPT), AST (SGOT), GGT, alkaline phosphatase and serum will be tested.
    • Any single parameter of ALT, AST, GGT, alkaline phosphatase or serum bilirubin must not exceed the (ULN)
    • History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or BUN and/or urea values, or abnormal urinary constituents (e.g. albuminuria).
    • Evidence of urinary obstruction or difficulty in voiding at screening.
  15. Use of any prescription drugs, herbal supplements, prescribed medicinal use of cannabis/marijuana, within four weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two weeks prior to initial dosing. If needed, (i.e. an incidental and limited need) paracetamol/acetaminophen is acceptable, but must be documented in the Concomitant medications / Significant non-drug therapies page of the CRF.
  16. Smokers (use of tobacco/nicotine products 1 week prior to screening). Urine cotinine levels will be measured during screening and at each baseline for all participants. Smokers will be defined as any participant who reports tobacco use and/or who has a urine cotinine ≥ 200 ng/mL.
  17. History of drug abuse or unhealthy alcohol use# within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening and at baseline. #Unhealthy alcohol use is defined as a history of, or current alcohol misuse/abuse, defined as " >21 units for males and >14 units for females in the same week."
  18. History of recreational cannabis use within four weeks prior to dosing, or evidence of such use as indicated by the laboratory assays conducted during screening and baseline. This exclusion criterion applies even if cannabis use is legalized where the site is located. Any prescribed, medicinal use of cannabis is to be handled according to the prescription drug usage criteria defined above.
  19. Pregnant or nursing (lactating) women.
  20. Sexually active males unwilling to use a condom during intercourse while taking drug and for 5 half-lives or 14 days after stopping investigational drug, whichever is longer. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner for 5 half-lives or 14 days after last dose, whichever is longer. In addition, male participants should not donate sperm for the time period specified above. Additionally, the female partners of male participants should also use an effective method of .
  21. Women of , defined as all women physiologically capable of becoming pregnant. Women are considered or not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks before screening. In the case of oophorectomy alone, only when the reproductive status of the women has been confirmed by follow-up hormone level assessment if she is considered not of child-bearing potential. Refer to Section 8.6.6 Pregnancy and Assessments of Fertility.
  22. Use of other investigational drugs at the time of enrollment or within 90 days of first dose in this study, or within 5 half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  23. Participants who do not have suitable veins for multiple venipuncture cannulation as assessed by the investigator of delegate at screening
  24. Participants in the food effect cohort: history of cholecystectomy or gall stones
  25. Presence or history of clinically significant allergy requiring treatment as judged by the investigator. Hay fever is allowed unless it is active.
  26. Evidence of an active infection, including COVID-19
  27. Participants who are immediate family members to other participants
  28. Participants who have previously participated in another cohort for this study
  29. Known or current history of hemoglobinopathies including sickle cell disease
  30. Intake of grapefruit or grapefruit juice within 14 days prior to initial dosing. No grapefruit or grapefruit juice is allowed until 7 days following the last dose
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    INE963

    Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo

    Drug: INE 963

  • Placebo comparator
    Placebo group

    Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo

    Other: Placebo

Interventions

  • Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days

  • OtherPlacebo

    Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.

06

What researchers measure

Primary outcomes

  1. Number of Subjects with Significant Clinical Safety Labs, reporting SAEs and AEs and ECG findings

    Number of Subjects with Significant Clinical Safety Labs, reporting SAEs and AEs and ECG findings, as judged by investigator at each dose escalation review meetings

    Time frame: Dose escalation (21 days)

Secondary outcomes

  1. INE963 pharmacokinetic parameters AUC in SAD Part

    INE963 pharmacokinetic parameters (AUC) in SAD Part at specified timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 9, 12 and 16

  2. INE963 pharmacokinetic parameters Tmax in SAD Part

    INE963 pharmacokinetic parameters in SAD Part (Tmax) at the specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 9, 12 and 16

  3. INE963 pharmacokinetic parameters Cmax in SAD Part

    INE963 pharmacokinetic parameters (Cmax) in SAD Part at specified timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 9, 12 and 16

  4. INE963 pharmacokinetic parameters Vz/F in SAD Part

    INE963 pharmacokinetic parameters in SAD Part (Vz/F) at the specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 9, 12 and 16

  5. INE963 pharmacokinetic parameters T1/2 in SAD Part

    INE963 pharmacokinetic parameters in SAD Part (T1/2) at the specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 9, 12 and 16

  6. INE963 pharmacokinetic parameters in MAD Part (AUC)

    INE963 pharmacokinetic parameters in MAD Part (AUC) measured at specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 10, 11, 14 and Day 18

  7. INE963 pharmacokinetic parameters in MAD Part (Cmax)

    INE963 pharmacokinetic parameters in MAD Part (Cmax) measured at specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 10, 11, 14 and Day 18

  8. INE963 pharmacokinetic parameters in MAD Part (Tmax)

    INE963 pharmacokinetic parameters in MAD Part (Tmax) measured at specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 10, 11, 14 and Day 18

  9. INE963 pharmacokinetic parameters in MAD Part (Vz/F)

    INE963 pharmacokinetic parameters in MAD Part (Vz/F) measured at specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 10, 11, 14 and Day 18

  10. INE963 pharmacokinetic parameters in MAD Part (T1/2)

    INE963 pharmacokinetic parameters in MAD Part (T1/2) measured at specific timepoints

    Time frame: Day 1, 2, 3, 4, 6, 8, 10, 11, 14 and Day 18

  11. Baseline AAG concentration

    Alpha-1- acid glycoprotein (AAG) level will be taken at baseline for Part A and Part b.

    Time frame: Baseline

07

Study locations

1 site
  • Novartis Investigative Site
    Mere Way, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2022, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 21, 2021
StartActual
May 13, 2021
Primary completionActual
Nov 24, 2022
CompletionActual
Nov 24, 2022
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04896632
Responsible party
Sponsor
First posted
May 21, 2021
Start date
May 13, 2021
Primary completion
Nov 24, 2022
Completion
Nov 24, 2022
Last update
Sep 28, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INE963

Start the discussion